To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Alpha-galactosylceramide … - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Alpha-galactosylceramide enhances mucosal immunity to oral whole-cell cholera vaccines

Journal article
Authors C. J. H. Davitt
S. Longet
A. Albutti
V. Aversa
Stefan Nordqvist
B. Hackett
C. P. McEntee
M. Rosa
I. S. Coulter
Michael Lebens
Joshua Tobias
Jan Holmgren
E. C. Lavelle
Published in Mucosal Immunology
Volume 12
Pages 1055–1064
ISSN 1933-0219
Publication year 2019
Published at Institute of Biomedicine, Department of Microbiology and Immunology
Pages 1055–1064
Language en
Subject categories Immunology in the medical area


Cholera is a severe diarrheal disease caused by the bacterium Vibrio cholerae (V. cholerae) that results in 3–4 million cases globally with 100,000–150,000 deaths reported annually. Mostly confined to developing nations, current strategies to control the spread of cholera include the provision of safe drinking water and improved sanitation and hygiene, ideally in conjunction with oral vaccination. However, difficulties associated with the costs and logistics of these strategies have hampered their widespread implementation. Specific challenges pertaining to oral cholera vaccines (OCVs) include a lack of safe and effective adjuvants to further enhance gut immune responses, the complex and costly multicomponent vaccine manufacturing, limitations of conventional liquid formulation and the lack of an integrated delivery platform. Herein we describe the use of the orally active adjuvant α-Galactosylceramide (α-GalCer) to strongly enhance intestinal bacterium- and toxin-specific IgA responses to the OCV, Dukoral ® in C57BL/6 and BALB/c mice. We further demonstrate the mucosal immunogenicity of a novel multi-antigen, single-component whole-cell killed V. cholerae strain and the enhancement of its immunogenicity by adding α-GalCer. Finally, we report that combining these components and recombinant cholera toxin B subunit in the SmPill ® minisphere delivery system induced strong intestinal and systemic antigen-specific antibody responses. © 2019, The Author(s).

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?